UBS Maintains a 'Neutral' on Seattle Genetics (SGEN); Updating Model for 4Q10 Results
Tweet Send to a Friend
UBS maintains a 'Neutral' on Seattle Genetics (NASDAQ: SGEN), PT lowered to $16.50.
UBS analyst says, "Q4 financial results were ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst says, "Q4 financial results were ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
